Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.63 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6114995 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 | |
| Glutarate SCHEMBL29142253 | 0.91 | MEN1 (0.74) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 | |
| Glutarate SCHEMBL29142331 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 | |
| Bromide SCHEMBL571258 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 | |
| SCHEMBL28513046 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 | |
| SCHEMBL717073 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 | |
| Glutarate SCHEMBL29142297 | 0.84 | MEN1 (0.64) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 | |
| Bromide SCHEMBL29479433 | 0.84 | SMN1; SMN2 (0.85) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 | |
| Bromide SCHEMBL18834186 | 0.84 | SMN1; SMN2 (0.85) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 | |
| Bromide SCHEMBL17395315 | 0.84 | SMN1; SMN2 (0.85) | SMN1; SMN2MEN1KMT2AHSP90AA1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541591-B2 | Nanoparticle/dispersant complex, nanoparticle dispersion liquid, and nanoparticle/matrix-material complex | CANON KABUSHIKI KAISHA (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20110144061-A1 | NANOPARTICLE/DISPERSANT COMPLEX, NANOPARTICLE DISPERSION LIQUID, AND NANOPARTICLE/MATRIX-MATERIAL COMPLEX | CANON KABUSHIKI KAISHA (JP) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144061-A1 | NANOPARTICLE/DISPERSANT COMPLEX, NANOPARTICLE DISPERSION LIQUID, AND NANOPARTICLE/MATRIX-MATERIAL COMPLEX | RAB5IF, ORMDL3, SLC6A11 | SMN1; SMN2 1413/4885MEN1 433/4885KMT2A 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.